Biotechnology Swedish Orphan Biovitrum also known as Sobi, today announced that its contract with US pharm giant Pfizer for the manufacture of drug substance for ReFacto AF (moroctocog alfa)/Xyntha (ReFacto) has been amended due to clarity of final order volumes and will now expire in the first quarter of 2024, earlier than the previous expiry date at the end of 2025. 23 March 2022